Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

When It Comes To FTC M&A Review, The Times May Be A Changin'

Executive Summary

Spark signaled in an SEC filing that its merger with Roche could be delayed into 2020, fueling more speculation that FTC is increasing scrutiny over biopharma mergers.

Advertisement

Related Content

Psoriasis Drugs Poised For The Q2 Spotlight
Deal Watch: Altimmune Moves Into NASH With Purchase Of Spitfire
AbbVie Will Use Allergan Revenue To Fund Combined Firm's Large R&D Pipeline
In Merger Plot Twist, BMS Needs A Buyer For Celgene's Otezla, Raising New Questions
Roche Confident Spark Therapeutics Acquisition Will Complete In First Half
Roche $4.8bn Buy Sparks Hemophilia Gene Therapy Race
Will FTC Shakeup Impact Pharma?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC125508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel